Anthracyclines are a specific class of medications for adjuvant chemotherapy. They disrupt the enzymes (proteins that help chemical reactions in cells) that copy DNA during a cell’s life.

For decades, anthracyclines have been the gold standard of treatment for women with breast cancer, but that could be changing. Ever since Dennis J. Slamon, MD, director of clinical/translational ...

A retrospective analysis of four phase II trials and one phase III trial evaluated the prognostic impact of adjuvant anthracyclines on the efficacy of first-line epirubicin–paclitaxel regimens ...

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded.

SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at San Antonio ...

Additionally, the benefits of anthracyclines in lower-risk patients (RS 26–30) may have been difficult to measure because of the overall lower risk of recurrence in this population.

Anthracyclines disrupt tumor growth by binding to and blocking the function of topoisomerase II (TOP2). Topoisomerases break, twist, and reseal the phosphate backbone of DNA and, in so doing ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The long-term results did not make a compelling case for continued use of anthracyclines as adjuvant breast cancer therapy, according to the authors of an accompanying editorial. "A persistent ...

Anthracyclines are one of the most active agents for the treatment of breast cancer and are components of many adjuvant and palliative regimens. [1,2] Within the adjuvant setting, ...

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded.